SASA-RNA vaccine

SASA-RNA vaccine is an experimental **self-amplifying RNA COVID-19 vaccine** formulated in a **nanostructured lipid carrier** delivery system and designed to express the **SARS-CoV-2 spike protein** carrying the **D614G-2P-3Q** stabilizing mutations. In the cited preclinical context, it appears to be a **research designation** rather than a formal commercial or clinical development name. The vaccine functions by delivering replicating RNA into host cells, enabling intracellular amplification of the RNA template and enhanced spike antigen expression, which is intended to induce both neutralizing antibody and T-cell responses against SARS-CoV-2. Available context supports use in **preclinical animal studies** of COVID-19 vaccination, including heterologous prime-boost strategies, but does not clearly establish a named commercial developer, manufacturer, or clinical-stage program for this exact designation.

Other names

self-amplifying RNA vaccinesaRNA vaccineSARS-CoV-2 spike self-amplifying RNA vaccineSARS-CoV2 spike self-amplifying RNA vaccineSARS-CoV 2 spike self-amplifying RNA vaccine